TipRanks
Advertisement
Advertisement

SABS Stock Latest News

SAB Biotherapeutics Wins FDA Fast Track for SAB-142
Company AnnouncementsSAB Biotherapeutics Wins FDA Fast Track for SAB-142
1m ago
8K
SABS
SAB Biotherapeutics granted Fast Track designation for SAB-142
PremiumThe Fly
SAB Biotherapeutics granted Fast Track designation for SAB-142
20m ago
SABS
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial
PremiumCompany Announcements
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial
3M ago
8K
SABS
SAB Biotherapeutics initiated with an Overweight at Barclays
PremiumThe Fly
SAB Biotherapeutics initiated with an Overweight at Barclays
4M ago
SABS
SAB Biotherapeutics Shareholders Back Board and Auditor
PremiumCompany Announcements
SAB Biotherapeutics Shareholders Back Board and Auditor
4M ago
8K
SABS
SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
PremiumRatingsSAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
4M ago
SABS
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
Premium
Ratings
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
4M ago
SABS
SAB Biotherapeutics initiated with a Buy at Citi
Premium
The Fly
SAB Biotherapeutics initiated with a Buy at Citi
5M ago
SABS
SAB Biotherapeutics initiated with a Buy at Jefferies
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Jefferies
5M ago
SABS
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
PremiumThe Fly
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
5M ago
SABS
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
PremiumCompany Announcements
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
5M ago
8K
SABS
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
PremiumThe Fly
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
6M ago
EBS
SABS
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
PremiumRatingsBuy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
6M ago
SABS
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
Premium
Company Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
6M ago
8K
SABS
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
6M ago
SABS
SABS Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SABS Upcoming Earnings Report: What to Expect?
7M ago
SABS
SAB Biotherapeutics Launches Major Equity Financing Offering
PremiumCompany Announcements
SAB Biotherapeutics Launches Major Equity Financing Offering
7M ago
8K
SABS
SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
PremiumThe Fly
SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
7M ago
SABS
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
PremiumThe Fly
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
7M ago
SABS
SAB Biotherapeutics announces common stock offering, no amount given
PremiumThe FlySAB Biotherapeutics announces common stock offering, no amount given
7M ago
SABS
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
Premium
The Fly
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
7M ago
SABS
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
Premium
Company Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
7M ago
8K
SABS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >